3 04, 2024

Decoding Population Health Analytics: Powering Pharma R&D and Clinical Decision Support

2024-04-03T16:38:30-05:00

Summary: Decode Health has built a mature AI/ML platform to accelerate clinical decision-making and population health analytics solutions. Check out the article below to learn more about recent collaborative efforts with a global pharmaceutical company and leading technology firm to better detect disease and identify patients at risk of high-cost events using predictive approaches in oncology and autoimmune disease.

Decoding Population Health Analytics: Powering Pharma R&D and Clinical Decision Support2024-04-03T16:38:30-05:00
26 03, 2024

Garbage In, Garbage Out: Data Quality is Essential for RNA Biomarker Discovery

2024-03-27T13:49:55-05:00

At Decode Health, we empower the healthcare industry to implement and leverage artificial intelligence (AI) approaches, including machine learning, across a wide range of clinical applications. Data quality is paramount, especially when utilizing large, disparate datasets to address complex diseases. Decode has developed a platform that ensures the precision and reproducibility of insights and results from diverse data sources. The platform features a robust quality control (QC) framework that optimizes the efficiency and accuracy of biomarker discovery. Check out the article below to learn how our technology accelerates the biomarker discovery R&D process, widens the impact of personalized medicine, and unlocks new insights to fuel better ways to diagnose and treat patients.

Garbage In, Garbage Out: Data Quality is Essential for RNA Biomarker Discovery2024-03-27T13:49:55-05:00
8 03, 2024

Decode Health Biomarker Discovery Platform Advances Findings in MS and NMO

2024-03-27T13:53:07-05:00

Decode Health deployed its biomarker discovery platform, incorporating machine learning, to provide new insights into multiple sclerosis (MS) and neuromyelitis optica (NMO). The Decode platform identified disease-specific RNA biomarkers and connections between RNA expression [read more...]

Decode Health Biomarker Discovery Platform Advances Findings in MS and NMO2024-03-27T13:53:07-05:00
7 02, 2023

Healthcare AI: Accelerating Innovation to Advance Precision Medicine

2023-04-24T11:47:38-05:00

For decades, healthcare and policy leaders have developed plans to reduce federal healthcare spending, which reached $4.3 trillion in 2021. Given recent economic shifts globally and domestically, finding solutions to mitigate healthcare costs has become even more important. Few sustainable solutions exist, and additional, more complex healthcare issues continue to emerge.

Healthcare AI: Accelerating Innovation to Advance Precision Medicine2023-04-24T11:47:38-05:00
23 11, 2022

Decode Health’s Key Takeaways from HLTH 2022

2023-04-24T11:47:38-05:00

Last week’s fifth annual HLTH conference in Las Vegas was the biggest and boldest yet. The event was overflowing with interesting information and innovative ideas that push to define healthcare for the next decade. Many of the topics discussed tie directly to the work we do at Decode Health. Here are our team’s takeaways.

Decode Health’s Key Takeaways from HLTH 20222023-04-24T11:47:38-05:00
30 08, 2022

Biomarker Discovery to Improve Clinical Trials and Advance Precision Medicine

2023-04-24T11:47:39-05:00

In the U.S., the cost of chronic diseases is more than $3.7T1 annually. Massive amounts of healthcare data are generated through wearable data, healthcare claims, electronic health records, and even complex genomic datasets. By 2025, the average individual will accumulate more than 4,900 daily digital device interactions2. Data alone, however, isn't the answer. The key is to find patterns within the data to proactively intervene and reduce the inefficiency within the $808 billion3 healthcare industry.

Biomarker Discovery to Improve Clinical Trials and Advance Precision Medicine2023-04-24T11:47:39-05:00
27 05, 2021

Battling the Economic Toll of SARS-CoV-2 with Predictive Analytics

2023-04-24T11:47:41-05:00

According to an article in the Journal of the American Medical Association (JAMA), two Harvard economists estimate the cumulative financial costs of the COVID-19 pandemic at more than $16 trillion. To put this number into perspective, that’s approximately 90% of annual GDP of the United States or $200,000 for a family of four. This is a combination of lost income due to the COVID-induced recession and the economic effect of a shorter, less healthy life.

Battling the Economic Toll of SARS-CoV-2 with Predictive Analytics2023-04-24T11:47:41-05:00
Go to Top